Victoria Socha

DocwireNews

Boston&mdash;For patients with chronic kidney disease (CKD) with anemia, clinical guidelines recommend erythropoietin-stimulating agents (ESA), oral or intravenous (IV) iron, or red blood cell transfusions. The treatment recommendations depend on hemoglobin level and prior treatment. The economic implications of the treatment decisions are uncertain.Tara Lavelle, PhD, and colleagues recently conducted a review of published cost-effective analyses to improve understanding of study methods and results used in those models. Results of the review were reported during a poster session at the NKF Spring Clinical Meetings in a poster titled A Review of Cost-Effectiveness Analyses for Anemia in Chronic Kidney Disease.The search included the TUFTS cost-effectiveness analysis (CEA) registry, Medline, and EMBASE, as well as conference abstract libraries for CEAs specific to CKD anemia published between January 2000, and May 2018. Keywords specific to anemia, CKD, and CEA were searched. Predefined eligibility criteria were used to screen studies; relevant data were abstracted from eligible studies.A total of 128 studies were identified; of those, eight met eligibility criteria. Half were CEAs of pharmacotherapies (eg, ESA vs no ESA, oral vs IV iron) and half examined modified approaches for healthcare delivery (eg, specialist-managed care). In five CEAS, Markov models were used, and three were piggyback cost analyses (two on clinical trials and one on cohort studies). Time horizons varied from 5 weeks to a lifetime, countries were mostly United States and Canada (three each), and two reported results from the societal perspective. Seven of the eight CEAs incorporated sensitivity analyses (one-way and/or probabilistic).In five CEAs, the study population included dialysis-dependent patients, including one that demonstrated IV iron was cost-effective compared with oral iron, particularly in patients &lt;45 years of age. Two CEAs compared ESA to red blood cell transfusion; results demonstrated that ESA was cost-effective in a 10-year model but not over a lifetime in a Canadian model. However, the Canadian model did show improvement in cost-effectiveness&nbsp; with the use of lower hemoglobin targets (9-11 vs &gt;12 g/dL). Two CEAs found that specialist-managed care by a nephrologist or pharmacist was cost-effective compared with standard care for non&ndash;dialysis-dependent patients.In summary, the researchers said, &ldquo;Few CEAs have been published in CKD anemia, and between-study variability exists, contributing to discrepant results. Research teams can leverage these review findings when considering different approaches for new CEAs that will help stakeholders better understand the economic implications of treatment decisions for CKD anemia in today&rsquo;s healthcare system.&rdquo;Source: Lavelle T, Michalopoulos S, Margaretos N, et al. A review of cost-effectiveness analyses for anemia in chronic kidney disease. Abstract of a poster presented during the National Kidney Foundation 2019 Spring Clinical Meetings, May 8-12, 2019, Boston, Massachusetts.

Jordana Jampel

Mechanism of Positive Association Between Parkinson’s Disease and Melanoma Revealed in New Research

Melanoma

Hatem Soliman, MD

Using Dendritic Cell Vaccines to Boost Neoadjuvant Therapy in HER2+ Breast Cancer

HER2 Breast Cancer

Kathleen Liu, MD

Joel M. Topf, MD, FACP

AKI Approaches and ASN Kidney Health Guidance

NKF Spring Clinical Meetings 2025

Latest News

Cost-Effectiveness of Treatments for Anemia in CKD

Chronic Kidney Disease

For patients with chronic kidney disease (CKD) with anemia, clinical guidelines recommend erythropoietin-stimulating agents (ESA), oral or intravenous (IV) iron, or red blood ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe